Prognostic value of DNA ploidy and nuclear morphometry in prostate cancer treated with androgen deprivation

Urology

Volumn 59, Issue 5, 2002, Pages 715-720

  Martínez Jabaloyas, José M ^a,b   Ruiz Cerdá, José L ^a   Hernández, Miguel ^a   Jiménez, Ana ^a   Jiménez Cruz, Fernando ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; HORMONE;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DNA CONTENT; FLOW CYTOMETRY; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MORPHOMETRICS; MULTIVARIATE ANALYSIS; PATHOLOGY; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS;

AGED; BIOPSY, NEEDLE; CELL NUCLEUS; FLOW CYTOMETRY; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PLOIDIES; PROGNOSIS; PROSTATE; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 0036242947     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(02)01530-3     Document Type: Article

References (26)

1. Value of deoxyribonucleic acid ploidy and nuclear morphometry for prediction of disease progression in renal cell carcinoma
2. Consensus review of the clinical utility of DNA content cytometry in prostate cancer
3. Practical clinical utility of DNA ploidy for managing patients with prostate carcinoma
4. A new method to assess metastatic potential of human prostate cancer: Relative nuclear roundness
5. Radical prostatectomy: Anatomical predictors of success or failure
6. Quantitative nuclear morphometry, markovian texture descriptors, and DNA content captured on a CAS-200 image analysis system, combined with PCNA and HER-2/neu immunohistochemistry for prediction of prostate cancer progression
7. Nuclear morphometry is of independent prognostic value only in T1 prostatic adenocarcinomas
8. High and low risk prostate carcinoma determined by histologic grade and proliferative activity
9. Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry
10. Use of nuclear morphometry, Gleason histologic scoring, clinical stage and age to predict disease-free survival among patients with prostate cancer
11. Prognostic value of deoxyribonucleic acid content in prostate cancer: A review of current results
12. Nuclear deoxyribonucleic acid determination in patients with prostate carcinomas: Clinical research and application
13. The prognostic significance of nuclear DNA content in prostatic carcinoma
14. The prognostic value of deoxyribonucleic acid flow cytometric analysis in stage D2 prostatic carcinoma
15. DNA ploidy and survival of patients with clinically localized prostate cancer treated without intent to cure
16. Stage D1 prostate cancer treated by radical prostatectomy and adjuvant hormonal treatment: Evidence for favorable survival in patients with DNA diploid tumors
17. DNA ploidy measurements in prostate cancer: Differences between image analysis and flow cytometry and clinical implications
18. A comparison of nuclear morphometry and Gleason grade as a predictor of prognosis in stage A2 prostate cancer: A critical analysis
19. Morphometrically estimated variation in nuclear size: A useful tool in grading prostatic cancer
20. Stereologically estimated mean nuclear volume of prostatic cancer is a reliable prognostic parameter
21. Prognostic value of nuclear morphometry on needle biopsy from patients with prostate cancer: Is volume-weighted mean nuclear volume superior to other morphometric parameters?
22. Ability to predict biochemical progression using Gleason score and a computer-generated quantitative nuclear grade derived from cancer cell nuclei
23. Genetically engineered neural networks for predicting prostate cancer progression after radical prostatectomy
24. High and low risk prostate carcinoma determined by histologic grade and proliferative activity